- Home
- FPH vs RIGL Comparison
FPH vs RIGL Comparison
Compare FPH & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FPH
- RIGL
- Stock Information
- Founded
- FPH 2009
- RIGL 1996
- Country
- FPH United States
- RIGL United States
- Employees
- FPH N/A
- RIGL N/A
- Industry
- FPH Real Estate
- RIGL Biotechnology: Pharmaceutical Preparations
- Sector
- FPH Finance
- RIGL Health Care
- Exchange
- FPH Nasdaq
- RIGL Nasdaq
- Market Cap
- FPH 398.9M
- RIGL 366.5M
- IPO Year
- FPH 2017
- RIGL 2000
- Fundamental
- Price
- FPH $5.31
- RIGL $17.15
- Analyst Decision
- FPH
- RIGL Buy
- Analyst Count
- FPH 0
- RIGL 5
- Target Price
- FPH N/A
- RIGL $36.80
- AVG Volume (30 Days)
- FPH 168.1K
- RIGL 253.6K
- Earning Date
- FPH 04-17-2025
- RIGL 03-04-2025
- Dividend Yield
- FPH N/A
- RIGL N/A
- EPS Growth
- FPH 25.45
- RIGL N/A
- EPS
- FPH 0.96
- RIGL 0.99
- Revenue
- FPH $237,926,000.00
- RIGL $179,278,000.00
- Revenue This Year
- FPH N/A
- RIGL $14.19
- Revenue Next Year
- FPH N/A
- RIGL $13.10
- P/E Ratio
- FPH $5.57
- RIGL $17.17
- Revenue Growth
- FPH 12.37
- RIGL 54.71
- 52 Week Low
- FPH $2.83
- RIGL $7.48
- 52 Week High
- FPH $6.71
- RIGL $29.82
- Technical
- Relative Strength Index (RSI)
- FPH 45.48
- RIGL 32.74
- Support Level
- FPH $5.17
- RIGL $19.81
- Resistance Level
- FPH $5.60
- RIGL $19.97
- Average True Range (ATR)
- FPH 0.20
- RIGL 1.04
- MACD
- FPH -0.03
- RIGL -0.31
- Stochastic Oscillator
- FPH 27.15
- RIGL 5.83
About FPH Five Point Holdings LLC
Five Point Holdings LLC is an owner and developer of mixed-use, master-planned communities in California. It is engaged in developing new communities that, in addition to homesites, include commercial, retail, educational and recreational elements, as well as civic areas, parks, and open spaces. Its four reportable segments are Valencia, San Francisco, Great Park, and Commercial. It derives the majority of revenue from the Great Park segment which includes Great Park Neighborhoods being developed adjacent to and around the Orange County Great Park, a metropolitan park under construction in Orange County, California.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.